论文部分内容阅读
孕激素治疗可以增加乳腺癌的风险。文章的实验数据对激素治疗中所有可用的孕激素和激素类避孕药中所有的孕激素进行了比较,结果表明,孕激素对乳腺癌发生风险的影响可能存在差异,尤其对正常乳腺上皮细胞和恶性乳腺上皮细胞风险存在差异。妇女健康启动(WHI)研究表明,不同于单一雌激素治疗,雌孕激素联合治疗可增加乳腺癌风险。然而,目前的临床研究没有区分孕激素的种类,大部分研究数据较少,并且大多数研究中采用的是安宫黄体酮或炔诺酮。然而证据表明,黄体酮和地屈孕酮对乳腺癌的风险可能较低,这还需要进一步的临床研究。绝经后的乳腺癌患者是否可以应用激素治疗?因数据极少,尚不能为临床提供有价值的参考依据,但国际绝经学会及中国绝经学组激素治疗指南均将乳腺癌患者列为绝经激素治疗的禁忌。
Progestin therapy can increase the risk of breast cancer. The experimental data in this paper compare all available progestins in hormonal therapy with those in hormonal contraceptives. The results show that the effects of progestins on the risk of breast cancer may be different, especially for normal breast epithelial cells and There are differences in the risk of malignant mammary epithelial cells. Women’s Health Initiative (WHI) studies show that, unlike single estrogen therapy, estrogen and progesterone combination therapy can increase the risk of breast cancer. However, the current clinical studies do not distinguish between progestin types, most of the research data is less, and in most of the studies used is progesterone or norethindrone. However, evidence suggests that the risk of progesterone and dydrogesterone on breast cancer may be low, which requires further clinical studies. Postmenopausal breast cancer patients can use hormone therapy? Because of very few data, yet can not provide a valuable reference for the clinical, but the International Menopause Society and Chinese menopause hormone therapy guidelines are breast cancer patients as hormone therapy Taboo.